Abstract: The invention relates to extended release pharmaceutical compositions of venlafaxine or pharmaceutically acceptable salts. More particularly this invention relates to a pharmaceutical composition having a core comprising venlafaxine and a coating thereupon. The coating utilizes at least one water insoluble polymer and at least one polymer having pH dependent solubility to delay and modulate the release of the drug in an extended manner.

Abstract: A solid pharmaceutical dosage form comprises a substrate containing an active agent and a solid composition deposited onto areas of a surface of the substrate and containing an active agent.

Abstract: Pioglitazone or a salt thereof having a particle size distribution wherein D90 is about 25 ?m to about 40 ?m, and pharmaceutical compositions prepared therefrom.

Abstract: Pharmaceutical compositions comprising memantine or a salt thereof, from which less than about 80% of the contained memantine dissolves into a pH 1.2 aqueous medium within about 60 minutes.

Abstract: Compositions comprising amorphous substituted benzimidazole compounds.

Abstract: Solid pharmaceutical compositions comprising a diphosphonic acid or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, enantiomer or racemic mixture thereof. The invention includes compositions with inner and outer phases, wherein the inner phase comprises no more than about 80% w/w and the outer phase comprises at least about 20% w/w.

Abstract: Stable liquid pharmaceutical compositions comprise granisetron or a pharmaceutically acceptable salt thereof.

Abstract: Pharmaceutical compositions comprise beta-adrenergic receptor blocking agents for controlled release and diuretics for immediate release. In an embodiment, a composition comprising metoprolol succinate is coated onto inert particles, and the particles are further coated with a polymer to provide controlled release of metoprolol. The coated particles are coated, granulated, or mixed with a composition comprising hydrochlorothiazide, then are compressed into tablets, or the coated particles are compressed into tablets and the tablets are coated with a composition comprising hydrochlorothiazide.

Abstract: Multi-particulate pharmaceutical compositions comprising an antihistamine for immediate release and a decongestant for modified release.

Abstract: Pharmaceutical compositions comprising a valproic acid drug compound, providing modified release of the drug.

Abstract: The present invention provides processes to prepare atorvastatin calcium Form VI, pharmaceutical compositions comprising atorvastatin calcium Form VI, and processes to prepare said compositions. An aspect of the invention relates to atorvastatin calcium Form VI compositions having enhanced bioavailability when administered orally to humans.

Abstract: Pharmaceutical compositions comprising bicalutamide or its pharmaceutically acceptable salts, solvates, single isomers, enantiomers or mixtures thereof, and a hydrophilic excipient, processes for preparing the compositions and finished dosage forms containing them, and methods of use and treatment.

Abstract: A process for preparing ramipril, and stable pharmaceutical compositions containing ramipril.

Abstract: The present invention provides an orally administrable capsule comprising at least two mini-tablets, or at least two mini-capsules, or a combination of at least a mini-tablet and a mini-capsule, wherein one of said mini-tablet or mini-capsule comprises a nonsteroidal anti-inflammatory drug and the other mini-tablet or mini-capsule comprises a prostaglandin.

Abstract: Mini-tablets comprising a drug substance are formed by compression, using forces sufficiently low to preserve the polymorphic form of the drug. The mini-tablets can be administered directly, filled into capsules, etc.

Abstract: The present invention relates to pharmaceutical compositions comprising simvastatin or pharmaceutically acceptable salts, solvates, enantiomers or mixtures thereof, processes for preparing the same and methods of use and treatment.

Abstract: The present invention relates to extended release pharmaceutical compositions comprising a beta-blocker drug or a pharmaceutically acceptable salt thereof, wherein said composition comprises at least two extended release portions, each portion having an in vitro dissolution profile that is different from another portion.

Abstract: The present invention relates to a process for the preparation of primidone. It also relates to compositions comprising primidone of desired particle size distribution, processes for the preparation of such particles and processes for the preparation of the compositions.

Abstract: A pharmaceutical dosage form, comprising an outer capsule containing at least one capsule, tablet, and/or particles comprising different drug substances.

Abstract: Pharmaceutical compositions comprising non-benzodiazepine hypnotic drugs or their pharmaceutically acceptable salts, solvates, enantiomers or mixtures and processes for preparing the same. The invention also includes immediate release and extended release pharmaceutical compositions comprising non-benzodiazepine hypnotic drugs, useful for sleep induction and sleep maintenance.